title: The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.
abstract: OBJECTIVE
  To determine the effects of glucagon-like peptide-1 receptor agonists compared with placebo and other anti-diabetic agents on weight loss in overweight or obese patients with type 2 diabetes mellitus.
  
  
  METHODS
  Electronic searches were conducted for randomised controlled trials that compared a glucagon-like peptide-1 receptor agonist therapy at a clinically relevant dose with a comparator treatment (other type 2 diabetes treatment or placebo) in adults with type 2 diabetes and a mean body mass index ≥ 25 kg/m2. Pair-wise meta-analyses and mixed treatment comparisons were conducted to examine the difference in weight change at six months between the glucagon-like peptide-1 receptor agonists and each comparator.
  
  
  RESULTS
  In the mixed treatment comparison (27 trials), the glucagon-like peptide-1 receptor agonists were the most successful in terms of weight loss; exenatide 2 mg/week: -1.62 kg (95% CrI: -2.95 kg, -0.30 kg), exenatide 20 μg: -1.37 kg (95% CI: -222 kg, -0.52 kg), liraglutide 1.2 mg: -1.01 kg (95%CrI: -2.41 kg, 0.38 kg) and liraglutide 1.8 mg: -1.51 kg (95% CI: -2.67 kg, -0.37 kg) compared with placebo. There were no differences between the GLP-1 receptor agonists in terms of weight loss.
  
  
  CONCLUSIONS
  This review provides evidence that glucagon-like peptide-1 receptor agonist therapies are associated with weight loss in overweight or obese patients with type 2 diabetes with no difference in weight loss seen between the different types of GLP-1 receptor agonists assessed.
authors.affiliation: University of Leicester, Department of Health Sciences, Leicester, United Kingdom.
authors.forename: Jessica E
authors.initials: JE
authors.lastname: Potts
authors.affiliation: University of Leicester, Department of Health Sciences, Leicester, United Kingdom.
authors.forename: Laura J
authors.initials: LJ
authors.lastname: Gray
authors.affiliation: Leicester Diabetes Centre, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom.
authors.forename: Emer M
authors.initials: EM
authors.lastname: Brady
authors.affiliation: University of Leicester, Diabetes Research Centre, Leicester, United Kingdom.
authors.forename: Kamlesh
authors.initials: K
authors.lastname: Khunti
authors.affiliation: University of Leicester, Diabetes Research Centre, Leicester, United Kingdom.
authors.forename: Melanie J
authors.initials: MJ
authors.lastname: Davies
authors.affiliation: University of Leicester, Diabetes Research Centre, Leicester, United Kingdom.
authors.forename: Danielle H
authors.initials: DH
authors.lastname: Bodicoat
mesh_terms: D000328:Adult; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000473:pathology; D000077270:Exenatide; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D000069450:Liraglutide / Q000008:administration & dosage; D008297:Male; D010455:Peptides / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D014688:Venoms / Q000008:administration & dosage; D015431:Weight Loss / Q000187:drug effects*; D000097789:Glucagon-Like Peptide-1 Receptor Agonists; D000067757:Glucagon-Like Peptide-1 Receptor
chemical_list: D000077270:Exenatide; D007004:Hypoglycemic Agents; D000069450:Liraglutide; D010455:Peptides; D014688:Venoms; D000097789:Glucagon-Like Peptide-1 Receptor Agonists; C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor